An observational study of alemtuzumab following fingolimod for multiple sclerosis. (2017)

First Author: Willis M
Attributed to:  MRC Centre for Neuropsychiatric Genetics and Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1212/nxi.0000000000000320

PubMed Identifier: 28101520

Publication URI: http://europepmc.org/abstract/MED/28101520

Type: Journal Article/Review

Volume: 4

Parent Publication: Neurology(R) neuroimmunology & neuroinflammation

Issue: 2

ISSN: 2332-7812